Laboratoire de R&D-Agents Transmissibles par Transfusion (R&D-ATT), Etablissement Français du Sang Pyrénées-Méditerranée, Montpellier, France.
Transfusion. 2010 Sep;50(9):2032-45. doi: 10.1111/j.1537-2995.2010.02678.x.
Transfusion safety relating to blood-transmissible agents is a major public health concern, particularly when faced with the continuing emergence of new infectious agents. These include new viruses appearing alongside other known reemerging viruses (West Nile virus, Chikungunya) as well as new strains of bacteria and parasites (Plasmodium falciparum, Trypanosoma cruzi) and finally pathologic prion protein (variant Creutzfeldt-Jakob disease). Genomic mutations of known viruses (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) can also be at the origin of variants susceptible to escaping detection by diagnostic tests. New technologies that would allow the simultaneous detection of several blood-transmissible agents are now needed for the development and improvement of screening strategies. DNA microarrays have been developed for use in immunohematology laboratories for blood group genotyping. Their application in the detection of infectious agents, however, has been hindered by additional technological hurdles. For instance, the variability among and within genomes of interest complicate target amplification and multiplex analysis. Advances in biosensor technologies based on alternative detection strategies have offered new perspectives on pathogen detection; however, whether they are adaptable to diagnostic applications testing biologic fluids is under debate. Elsewhere, current nanotechnologies now offer new tools to improve the sample preparation, target capture, and detection steps. Second-generation devices combining micro- and nanotechnologies have brought us one step closer to the potential development of innovative and multiplexed approaches applicable to the screening of blood for transmissible agents.
与血液传播病原体相关的输血安全是一个主要的公共卫生关注点,特别是在面对新的传染性病原体不断出现时。这些病原体包括与其他已知再出现的病毒(西尼罗河病毒、基孔肯雅热)一起出现的新病毒,以及新的细菌和寄生虫菌株(恶性疟原虫、克氏锥虫),最后还有病理性朊病毒蛋白(变异型克雅氏病)。已知病毒(乙型肝炎病毒、丙型肝炎病毒、人类免疫缺陷病毒)的基因组突变也可能导致易于逃避诊断检测的变异体。为了开发和改进筛选策略,现在需要新的技术来同时检测几种血液传播病原体。DNA 微阵列已开发用于免疫血液学实验室进行血型基因分型。然而,它们在传染病原体检测中的应用受到了额外的技术障碍的阻碍。例如,感兴趣的基因组之间和内部的变异性使靶扩增和多重分析复杂化。基于替代检测策略的生物传感器技术的进步为病原体检测提供了新的视角;然而,它们是否适用于检测生物体液的诊断应用仍存在争议。在其他地方,当前的纳米技术现在提供了新的工具来改进样本制备、靶标捕获和检测步骤。结合微纳技术的第二代设备使我们更接近于潜在开发适用于血液传播病原体筛查的创新和多重方法。